Treatments

*May 2021* Dr. Heather Wakelee joins GRACE to discuss treatment options for a metastatic non small cell lung cancer diagnosis. Listen here.

*April 2021* MET amplification is a frequently observed mechanism of resistance to osimertinib, and coinhibition strategy of MET and EGFR revealed promising results in recent clinical trials. Nevertheless, acquired resistance mechanisms to combined EGFR and MET inhibition are poorly understood. In this study, we investigated the mechanisms of acquired resistance…

*May 2021* The combination of oleclumab (MEDI9447) and osimertinib (Tagrisso) was well-tolerated and demonstrated preliminary anti-tumor activity in patients with non-small-cell lung cancer (NSCLC) with an epidermal growth factor receptor mutation (EFGR) mutation after progression on an EGFR tyrosine kinase inhibitor (TKI), according to results from a phase 1B/2 study…

*May 2021* The U.S. Food and Drug Administration approved Rybrevant (amivantamab-vmjw) as the first treatment for adult patients with non-small cell lung cancer whose tumors have specific types of genetic mutations: epidermal growth factor receptor (EGFR) exon 20 insertion mutations. The FDA also approved the Guardant360 CDx (Guardant Health Inc.)…

*June 2021* This webinar focuses on necessary testing, common mechanisms of EGFR-dependent resistance, and possible treatment strategies. Dr. Josh Bauml and Dr. Melina Marmarelis, both from the University of Pennsylvania provide their expertise. Watch it here.

*April 2021* The FDA has granted a priority review designation to a new drug application (NDA) for mobocertinib (TAK-788) for the treatment of adult patients with EGFR exon 20 insertion mutation–positive metastatic non–small cell lung cancer (NSCLC), as detected via an FDA-approved assay, who have received previous platinum-based chemotherapy.1 The designation is…

*April 2021* In this podcast, Drs. H. Jack West, Helena Yu, and David Spigel discuss the addition of SBRT to a systemic EGFR inhibitor TKI in EGFR positive NSCLC. Listen here.

*April 2021* In this podcast, Drs. H. Jack West, Helena Yu, and David Spigel discuss the addition of SBRT to a systemic EGFR inhibitor TKI in EGFR positive NSCLC. Listen here.

*April 2021* Jyoti D. Patel, MD, discusses how the FDA approval of adjuvant osimertinib has impacted the treatment of patients with EGFR-positive NSCLC, efforts being made to overcome resistance to the third-generation EGFR TKI, and other approaches under exploration that may serve to further improve outcomes in this population. Read…

*April 2021* Tyrosine kinase inhibitors (TKIs) have dramatically changed the clinical prospects of patients with non-small cell lung cancer harboring epidermal growth factor receptor (EGFR)-activating mutations. Despite prolonged disease control and high tumor response rates, all patients eventually progress on EGFR TKI treatment. Here, we review the mechanisms of acquired…